NEW YORK, March 12, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on HTGM, PRAH, DGX, and TROV which can be accessed for free by signing up to www.wallstequities.com/registration. On Friday, March 09, 2018, US markets saw broad based gains
HTG Molecular Diagnostics
On Friday, shares in Tucson, Arizona-based HTG Molecular Diagnostics Inc. recorded a trading volume of 1.13 million shares. The stock ended the session 3.42% lower at $5.09. The Company's shares have gained 51.49% in the last month, 170.60% over the previous three months, and 87.82% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 33.37% and 89.07%, respectively. Moreover, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have a Relative Strength Index (RSI) of 61.57. Get the full research report on HTGM for free by clicking below at: www.wallstequities.com/registration/?symbol=HTGM
PRA Health Sciences
Raleigh, North Carolina headquartered PRA Health Sciences Inc.'s stock closed the day 2.90% higher at $90.46 with a total trading volume of 559,029 shares, which was above their three months average volume of 478.47 thousand shares. The Company's shares have advanced 11.05% in the previous three months and 54.03% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.39% and 11.99%, respectively. Additionally, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 59.49. Free research on PRAH can be accessed at: www.wallstequities.com/registration/?symbol=PRAH
Shares in Secaucus, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 1.03 million shares, which was above their three months average volume of 1.02 million shares. The stock ended last Friday's trading session 2.25% higher at $106.99. The Company's shares have advanced 9.86% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.92% and 4.85%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 62.56.
On March 07th, 2018, research firm Argus upgraded the Company's stock rating from 'Hold' to 'Buy'. Sign up today for the free research report on DGX at: www.wallstequities.com/registration/?symbol=DGX
San Diego, California headquartered TrovaGene Inc.'s stock finished Friday's session 1.12% higher at $0.36 with a total trading volume of 1.09 million shares. The Company's shares have advanced 7.63% in the last month. The stock is trading above its 50-day moving average by 11.74%. Additionally, shares of TrovaGene, which develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics, have an RSI of 54.66. Wall St. Equities' research coverage also includes the downloadable free report on TROV at: www.wallstequities.com/registration/?symbol=TROV
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-medical-research-equities----htg-molecular-diagnostics-pra-health-sciences-quest-diagnostics-and-trovagene-300612156.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!